Regulatory milestones

Amylin Pharmaceuticals Inc. (NASDAQ:AMLN) lost $0.65 to $21.10 last week after it submitted a response to a March complete response letter from FDA for an NDA for Bydureon exenatide once weekly to treat Type II diabetes. In addition, partner Eli Lilly and Co. (NYSE:LLY) submitted an MAA to the European Medicines Agency (EMA).

Lilly and Amylin co-developed the long-acting release (LAR) formulation of synthetic exendin-4. It uses drug delivery technology from Alkermes Inc. (NASDAQ:ALKS), which was off $0.13 to $13.35 on the week...